Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 2
2007 1
2008 2
2009 2
2010 2
2011 1
2012 3
2013 1
2014 3
2015 7
2016 11
2017 11
2018 5
2019 13
2020 15
2021 19
2022 22
2023 10
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
Ishihara M, Kitano S, Kageyama S, Miyahara Y, Yamamoto N, Kato H, Mishima H, Hattori H, Funakoshi T, Kojima T, Sasada T, Sato E, Okamoto S, Tomura D, Nukaya I, Chono H, Mineno J, Kairi MF, Diem Hoang Nguyen P, Simoni Y, Nardin A, Newell E, Fehlings M, Ikeda H, Watanabe T, Shiku H. Ishihara M, et al. Among authors: kitano s. J Immunother Cancer. 2022 Jun;10(6):e003811. doi: 10.1136/jitc-2021-003811. J Immunother Cancer. 2022. PMID: 35768164 Free PMC article. Clinical Trial.
Immunotherapy for genitourinary tumors.
Nakayama T, Kitano S. Nakayama T, et al. Among authors: kitano s. Int J Urol. 2019 Mar;26(3):326-333. doi: 10.1111/iju.13902. Epub 2019 Feb 1. Int J Urol. 2019. PMID: 30710374 Review.
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, Harada N, Miyahara Y, Seo N, Hattori H, Takada K, Emori M, Kakunaga S, Endo M, Matsumoto Y, Sasada T, Sato E, Yamada T, Matsumine A, Nagata Y, Watanabe T, Kageyama S, Shiku H. Ishihara M, et al. Among authors: kitano s. Int J Cancer. 2023 Jun 15;152(12):2554-2566. doi: 10.1002/ijc.34453. Epub 2023 Feb 17. Int J Cancer. 2023. PMID: 36727538 Clinical Trial.
Biomarkers for Immune Checkpoint Inhibitors in Melanoma.
Kitano S, Nakayama T, Yamashita M. Kitano S, et al. Front Oncol. 2018 Jul 18;8:270. doi: 10.3389/fonc.2018.00270. eCollection 2018. Front Oncol. 2018. PMID: 30073150 Free PMC article. Review.
Clinical Development of Immune Checkpoint Inhibitors.
Ito A, Kondo S, Tada K, Kitano S. Ito A, et al. Among authors: kitano s. Biomed Res Int. 2015;2015:605478. doi: 10.1155/2015/605478. Epub 2015 Jun 16. Biomed Res Int. 2015. PMID: 26161407 Free PMC article. Review.
Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations.
Aoki K, Nishito Y, Motoi N, Arai Y, Hiraoka N, Shibata T, Sonobe Y, Kayukawa Y, Hashimoto E, Takahashi M, Fujii E, Nishizawa T, Fukuda H, Ohashi K, Arai K, Mizoguchi Y, Yoshida Y, Watanabe SI, Yamashita M, Kitano S, Sakamoto H, Nagata Y, Mitsumori R, Ozaki K, Niida S, Kanai Y, Hirayama A, Soga T, Maruyama T, Tsukada K, Yabuki N, Shimada M, Kitazawa T, Natori O, Sawada N, Kato A, Yoshida T, Yasuda K, Mizuno H, Tsunoda H, Ochiai A. Aoki K, et al. Among authors: kitano s. Cancer Res Commun. 2023 Jun 13;3(6):1026-1040. doi: 10.1158/2767-9764.CRC-22-0415. eCollection 2023 Jun. Cancer Res Commun. 2023. PMID: 37377611 Free PMC article.
Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma.
Katsuya Y, Kitano S, Yamashita M, Ouchi M, Yagishita S, Hamada A, Nakamura H, Hosoda F, Shibata T, Motoi N, Nakayama T, Seto T, Umemura S, Hosomi Y, Satouchi M, Nishio M, Kozuki T, Hida T, Ohe Y, Horinouchi H. Katsuya Y, et al. Among authors: kitano s. Front Oncol. 2023 Jan 9;12:966527. doi: 10.3389/fonc.2022.966527. eCollection 2022. Front Oncol. 2023. PMID: 36698400 Free PMC article.
124 results